초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 03월 02일 17시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

제109회 대한화학회 학술발표회, 총회 및 기기전시회 안내 A potent chondrogenic small molecule in hBM-MSC

2012년 2월 29일 10시 42분 41초
MEDI.P-1028 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
4월 25일 (수요일) 18:00~21:00
저자 및
김종훈, 박승범1
서울대학교 화학과, Korea
1서울대학교 화학부, Korea
Mesencymal stem cells (MSCs), which are multipotent cells that can differentiate into cartilage, bone and adipose et al, can synthesize cartilage specific extracellular matrix (ECM) abundant in collagen type II and glycosaminoglycan (GAG) as the result of chondrogenesis in chemically defined medium including dexamethasone and transforming growth factor-β (TGF-β) superfamily such as TGF-β1, TGF-β3 and bone morphorgenetic protein (BMP). For this reason, the cell-based repair of articular cartilage defects using chondrocytes formed by the differenciation of MSCs should be expected to improve clinical outcome. However, it is a considerable factor that high doses TGF-β is able to generate undesired side effects such as synovitis, pannus formation, cartilage erosion or joint effusion and TGF-β levels are considered as a potential marker in cancer patients. Furthermore, TGF-β and dexamethasone are not specific chondrogenic differentiation factor. In recent, small molecules that can selectively control proliferation and differenciation of stem cells through the temporal perturbation of target biological materials have been emerging as alternative to nonspecific differenciation methods. Thus, the identification of potent and specific small molecule modulators credible alternative to TGF-β for inducing chondrogenesis should gain insight into the developmental mechanisms of MSCs and improve the efficiency of clinical trials. To address this issue, we report the novel synthetic small molecules 5a, which can selectively differentiate human bone marrow derived MSCs (hBM-MSCs) into chondrocyte.